M3814

DNA-PK-selective kinase inhibitor

oral efficacy in xenograft radiation models

undisclosed screening and optimization

Mol. Cancer Ther., Mar. 27, 2020

Merck KGaA, Darmstadt, DE

M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.